-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 19, 2022, Beijing time, Deqi Pharmaceutical Co.
Deqi Pharmaceutical's first new PD-L1/4-1BB bispecific antibody ATG-101 independently developed by Deqi Pharma has been certified as an orphan drug by the US Food and Drug Administration (FDA) for the treatment of pancreatic cancer
There is currently no approved PD-L1/4-1BB bispecific antibody
Orphan drug, also known as rare disease drugs, refers to drugs used to prevent, treat and diagnose rare diseases
The FDA grants orphan drug designation to help develop drug candidates that may benefit patients with rare diseases in the U.
ATG-101 is a novel PD-L1/4-1BB bispecific antibody that can block immunosuppressive PD-L1/PD-1 binding and conditionally activate 4-1BB co-stimulation signals, thereby activating anti-tumor immune effector cells and improving safety
ATG-101 is a novel PD-L1/4-1BB bispecific antibody that can block immunosuppressive PD-L1/PD-1 binding and conditionally activate 4-1BB co-stimulation signals, thereby activating anti-tumor immune effector cells and improving safety
Dr.
About Deqi MedicineDeqi Medicine doctors have no boundaries, innovation and sustainability
Since 2017, Deqi Pharma has now established an expanding pipeline of 15 clinical and preclinical products, of which 10 products have global interests and 5 products have Asia-Pacific interests